

Gianmauro Numico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8738093/publications.pdf>

Version: 2024-02-01

101
papers

3,275
citations

147801

31
h-index

161849

54
g-index

106
all docs

106
docs citations

106
times ranked

4792
citing authors

#	ARTICLE	IF	CITATIONS
1	Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units. <i>Internal and Emergency Medicine</i> , 2020, 15, 1011-1019.	2.0	6
2	The hospital care of patients with cancer: a retrospective analysis of the characteristics of their hospital stay in comparison with other medical conditions. <i>European Journal of Cancer</i> , 2020, 139, 99-106.	2.8	8
3	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , 2020, 98, 763-770.	1.9	9
4	ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients. <i>Journal of Molecular Pathology</i> , 2020, 1, 19-31.	1.2	2
5	Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. <i>JCO Oncology Practice</i> , 2020, 16, 142-145.	2.9	18
6	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
7	Toward uniform and controlled clinical pathways in cancer care: a qualitative description. <i>International Journal for Quality in Health Care</i> , 2019, 31, 781-786.	1.8	2
8	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	2.0	122
9	Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions. <i>Acta Clinica Belgica</i> , 2018, 73, 163-164.	1.2	1
10	Conflict of interest among Italian medical oncologists: a national survey. <i>BMJ Open</i> , 2018, 8, e020912.	1.9	4
11	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on <i>Lancet Oncology</i> . <i>Dentistry Journal</i> , 2018, 6, 42.	2.3	2
12	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	2.3	54
13	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	1.9	4
14	The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study. <i>International Journal of Health Policy and Management</i> , 2018, 7, 728-737.	0.9	3
15	Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 209-209.	1.6	2
16	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta Oncologica</i> , 2017, 56, 555-562.	1.8	24
17	Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 335-345.	2.4	19
18	Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 144-151.	4.4	51

#	ARTICLE	IF	CITATIONS
19	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	10.7	293
20	Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. <i>Future Oncology</i> , 2017, 13, 233-248.	2.4	8
21	Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis. <i>Scientific Reports</i> , 2017, 7, 17626.	3.3	7
22	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	2.5	45
23	Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. <i>Medicine (United States)</i> , 2016, 95, e3273.	1.0	18
24	RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw155.	6.3	5
25	Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. <i>Medical Oncology</i> , 2016, 33, 76.	2.5	4
26	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 100-106.	4.4	62
27	Malignant pleural mesothelioma (MPM): Outcome of 352 patients (pts) treated by a dedicated multidisciplinary team (MT) in the highly asbestos polluted area of Casale Monferrato, Piedmont (Italy).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20078-e20078.	1.6	0
28	Tracheal Metastasis. <i>Journal of Craniofacial Surgery</i> , 2015, 26, 982-983.	0.7	1
29	Bilateral Breast Radiation Delivered with Static Angle Tomotherapy (TomoDirect): Clinical Feasibility and Dosimetric Results of a Single Patient. <i>Tumori</i> , 2015, 101, e4-e8.	1.1	9
30	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 191-213.	4.4	33
31	Cancer survivorship. <i>Current Opinion in Oncology</i> , 2015, 27, 351-357.	2.4	41
32	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 167-182.	4.4	46
33	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 372-384.	4.4	95
34	Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost Combined with Concurrent Chemotherapy for the Treatment of Anal Cancer Patients: 4-Year Results of a Consecutive Case Series. <i>Cancer Investigation</i> , 2015, 33, 259-266.	1.3	42
35	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16059-e16059.	1.6	2
36	Hospital Admission of Cancer Patients: Avoidable Practice or Necessary Care?. <i>PLoS ONE</i> , 2015, 10, e0120827.	2.5	93

#	ARTICLE	IF	CITATIONS
37	Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists. PLoS ONE, 2014, 9, e101170.	2.5	8
38	Minimizing a Tricky Situation in Breast Irradiation with Helical Tomotherapy. Tumori, 2014, 100, e35-e40.	1.1	2
39	Palliative Radiotherapy for Painful Bone Metastases from Solid Tumors Delivered with Static Ports of Tomotherapy (TomoDirect): Feasibility and Clinical Results. Cancer Investigation, 2014, 32, 458-463.	1.3	4
40	Medical oncology: in search of a definition. Annals of Oncology, 2014, 25, 1075-1076.	1.2	1
41	Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers, 2014, 14, 151-162.	1.7	5
42	Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. Journal of Cancer Research and Clinical Oncology, 2014, 140, 167-177.	2.5	42
43	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Supportive Care in Cancer, 2014, 22, 1889-96.	2.2	23
44	Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?. Supportive Care in Cancer, 2014, 22, 2813-2819.	2.2	12
45	Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series. Medical Oncology, 2014, 31, 838.	2.5	21
46	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. Critical Reviews in Oncology/Hematology, 2014, 91, 130-141.	4.4	36
47	The Role of microRNA in Head and Neck Cancer: Current Knowledge and Perspectives. Molecules, 2014, 19, 5704-5716.	3.8	35
48	New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. Current Medicinal Chemistry, 2014, 21, 1039-1049.	2.4	7
49	Relationships between head and neck cancer patients and their caregivers: Focus on psychological distress and quality of life.. Journal of Clinical Oncology, 2014, 32, e20571-e20571.	1.6	0
50	Minimizing a tricky situation in breast irradiation with helical tomotherapy. Tumori, 2014, 100, e35-40.	1.1	0
51	Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Medical Oncology, 2013, 30, 518.	2.5	31
52	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology, 2013, 85, 112-120.	4.4	21
53	The Role of Neck Dissection after Radical Chemoradiation for Locally Advanced Head and Neck Cancer: Should We Move Back?. Oncology, 2013, 84, 174-185.	1.9	9
54	Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1927-1936.	2.5	41

#	ARTICLE	IF	CITATIONS
55	Nonsurgical Conservative Approach for Laryngeal Cancer: What Information Should Patients Be Given?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3168-3170.	1.6	4
56	Management of 'In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. <i>Oncology</i> , 2013, 85, 257-261.	1.9	11
57	Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus. <i>Tumori</i> , 2013, 99, e80-3.	1.1	9
58	Takotsubo Syndrome in a Patient Treated With Sunitinib for Renal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e218-e220.	1.6	34
59	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 2141-2147.	2.2	7
60	Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1051-1057.	1.5	44
61	Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways. <i>Radiation Oncology</i> , 2012, 7, 21.	2.7	13
62	Radiation-induced pemphigus vulgaris of the breast. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2011, 15, 334-337.	1.4	10
63	Advances in EGFR-directed therapy in head and neck cancer. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 454-466.	2.1	10
64	TomoDirect: An efficient means to deliver radiation at static angles with tomotherapy. <i>Tumori</i> , 2011, 97, 498-502.	1.1	33
65	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. <i>Current Drug Metabolism</i> , 2011, 12, 918-931.	1.2	11
66	Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. <i>Supportive Care in Cancer</i> , 2011, 19, 1823-1830.	2.2	21
67	Cetuximab-Related Radiation Dermatitis in Head-and-Neck Cancer Patients: In Regard to Studer et al. (Int J Radiat Oncol Biol Phys) 79, 1278.	1.0784314	2
68	Radiotherapy in Pleural Malignant Mesothelioma: Why not! in Regard to Scorsetti et al. (Int J Radiat Oncol Biol Phys) 79, 1279.	0.8	0
69	Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. <i>Annals of Oncology</i> , 2011, 22, 712-717.	1.2	67
70	TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. <i>Tumori</i> , 2011, 97, 498-502.	1.1	29
71	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	7.7	15
72	The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. <i>Annals of Oncology</i> , 2009, 20, 941-945.	1.2	45

#	ARTICLE	IF	CITATIONS
73	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. <i>Oncology</i> , 2009, 77, 69-74.	1.9	16
74	Giant Borderline Phyllodes Tumor of the Breast. <i>Breast Journal</i> , 2008, 14, 203-204.	1.0	0
75	Role of gemcitabine in metastatic breast cancer patients: A short review. <i>Breast</i> , 2008, 17, 220-226.	2.2	47
76	Ultrathin Hydrocolloid Dressing in Skin Damaged From Alternating Radiotherapy and Chemotherapy Plus Cetuximab in Advanced Head and Neck Cancer (G.O.N.O. AlteRCC Italian Trial): In Regard to Macmillan et Al. (<i>Int J Radiat Oncol Biol Phys</i> 2007;68:864-872). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 638-639.	0.8	12
77	Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 25-32.	0.8	24
78	Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 731-737.	0.8	15
79	Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group. <i>Acta Oncologica</i> , 2006, 45, 168-174.	1.8	18
80	Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 223-226.	1.3	63
81	Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. <i>Cancer</i> , 2005, 103, 994-999.	4.1	186
82	Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. <i>Cancer</i> , 2005, 104, 1110-1111.	4.1	12
83	Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 271-276.	2.3	13
84	Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer. <i>Oncology</i> , 2005, 69, 273-282.	1.9	21
85	Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck. A phase II trial. <i>Radiotherapy and Oncology</i> , 2005, 75, 193-196.	0.6	14
86	Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. <i>Anticancer Research</i> , 2005, 25, 2555-9.	1.1	4
87	Empathy in the Doctor-Patient Relationship. <i>Journal of Clinical Oncology</i> , 2004, 22, 2258-2259.	1.6	11
88	A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2004, 15, 23-27.	1.4	6
89	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. <i>Cancer Cell</i> , 2003, 3, 387-402.	16.8	429
90	The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2003, 39, 353-357.	2.8	62

#	ARTICLE	IF	CITATIONS
91	Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. <i>Annals of Oncology</i> , 2002, 13, 331-333.	1.2	19
92	Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. <i>Lung Cancer</i> , 2002, 35, 59-64.	2.0	26
93	Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy?. <i>Lung Cancer</i> , 2001, 32, 213-226.	2.0	45
94	Gemcitabine, Cisplatin, and Radiation in Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 618-622.	1.3	27
95	Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2000, 83, 1437-1442.	6.4	11
96	Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity. <i>Journal of Clinical Oncology</i> , 2000, 18, 2116-2125.	1.6	44
97	Chemotherapy alternated with radiotherapy in the treatment of advanced head and neck carcinoma: predictive factors of outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 139-147.	0.8	9
98	5-Fluorouracil Dose Intensification and Granulocyte-Macrophage Colony-Stimulating Factor in Cisplatin-Based Chemotherapy for Relapsed Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 313-316.	1.3	1
99	Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: Results of a multivariate analysis on 273 patients. <i>Annals of Oncology</i> , 1997, 8, 773-779.	1.2	30
100	Pharmacokinetics of (6S)-Leucovorin and 5-Methyltetrahydrofolate after 4-Hour Continuous Intravenous Infusion Followed by Repeated Oral Doses of (6S)-Leucovorin in Patients with Colorectal Cancer Treated with 5-Fluorouracil. <i>Clinical Drug Investigation</i> , 1996, 12, 39-45.	2.2	0
101	Five-Year Update of a Randomized Trial of Alternating Radiotherapy and Chemotherapy Compared With Radiotherapy Alone in Treatment of Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 1996, 88, 583-589.	6.3	237